MA31067B1 - Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison. - Google Patents

Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison.

Info

Publication number
MA31067B1
MA31067B1 MA31972A MA31972A MA31067B1 MA 31067 B1 MA31067 B1 MA 31067B1 MA 31972 A MA31972 A MA 31972A MA 31972 A MA31972 A MA 31972A MA 31067 B1 MA31067 B1 MA 31067B1
Authority
MA
Morocco
Prior art keywords
compounds
methods
binding partners
bcl proteins
inhibiting interaction
Prior art date
Application number
MA31972A
Other languages
Arabic (ar)
English (en)
Inventor
Alfredo C Castro
Edward B Holson
Brian T Hopkins
Nii O Koney
Daniel A Snyder
Thomas T Tibbitts
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of MA31067B1 publication Critical patent/MA31067B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un aspect de la présente invention concerne des composés hétérocycliques qui lient les protéines bcl et inhibent la fonction bci. Un autre aspect de la présente invention concerne des compositions comprenant un composé hétérocyclique selon l'invention. La présente invention concerne des procédés de traitement et de modulation des troubles associés à l'hyperprolifération, tels que le cancer.
MA31972A 2006-11-15 2009-06-10 Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison. MA31067B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
PCT/US2007/023941 WO2008060569A1 (fr) 2006-11-15 2007-11-14 Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison

Publications (1)

Publication Number Publication Date
MA31067B1 true MA31067B1 (fr) 2010-01-04

Family

ID=39064388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31972A MA31067B1 (fr) 2006-11-15 2009-06-10 Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison.

Country Status (21)

Country Link
US (2) US7842815B2 (fr)
EP (1) EP2094673B1 (fr)
JP (2) JP2010510214A (fr)
KR (1) KR101530721B1 (fr)
CN (1) CN101583606B (fr)
AU (1) AU2007319848B2 (fr)
BR (1) BRPI0718606A2 (fr)
CA (1) CA2669596C (fr)
EC (1) ECSP099398A (fr)
ES (1) ES2537762T3 (fr)
GT (1) GT200900123A (fr)
HK (1) HK1130057A1 (fr)
IL (1) IL198597A (fr)
MA (1) MA31067B1 (fr)
MX (1) MX2009005184A (fr)
MY (1) MY156754A (fr)
NO (1) NO20092306L (fr)
NZ (1) NZ577243A (fr)
RU (1) RU2449996C2 (fr)
TN (1) TN2009000182A1 (fr)
WO (1) WO2008060569A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
GB2471588A (en) * 2008-02-08 2011-01-05 Aileron Therapeutics Inc Therapeutic peptidomimetic macrocycles
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
EP2812695A4 (fr) 2012-02-06 2015-12-02 Discoverx Corp Détection d'événements de liaison intracellulaire en mesurant l'abondance de protéines
AR089993A1 (es) 2012-02-15 2014-10-01 Aileron Therapeutics Inc Macrociclos peptidomimeticos
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
CN103656642A (zh) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 预防和治疗结直肠癌的方法和试剂
EP2961738B1 (fr) 2012-11-14 2019-12-25 CJ CheilJedang Corporation Production de sels de 4-hydroxybutyrate à l'aide de matières premières biosourcées
WO2014138429A2 (fr) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leur utilisation dans la régulation de hif1alpha
SG10201805670QA (en) 2014-01-28 2018-08-30 Buck Inst Res Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3347372A4 (fr) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques en tant que modulateurs de mcl-1
CA3018932C (fr) 2016-03-28 2021-10-26 Presage Biosciences, Inc. Combinaisons pharmaceutiques pour le traitement du cancer
EP3454856A4 (fr) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
EP3897631A4 (fr) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. Dégradation ciblée de protéines
WO2021233948A1 (fr) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de traitement d'une infection pulmonaire par un pathogène
EP4175644A1 (fr) 2020-07-06 2023-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinaison d'antibiotiques anti néoplasiques et d'inhibiteurs de bcl-2 pour le traitement de la leucémie myéloïde aiguë (lma) entraînée par npm-1

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
BR9008022A (pt) 1990-05-18 1993-04-06 Hoechst Ag Amida de acido isoxazol-4-carboxilico e amidas de acido hidroxialquilideno-cianoacetico,medicamentos contendo estes compostos e sua aplicacao
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
EP0730590B1 (fr) 1993-11-24 2001-01-17 Dupont Pharmaceuticals Company antagonistes de recepteur de fibrinogene, a base d'isoxazoline et d'isoxazole
WO1995024398A1 (fr) 1994-03-09 1995-09-14 Pfizer Inc. Composes d'isoxazoline utilise comme inhibiteurs de liberation du fnt
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
CA2262117A1 (fr) 1996-08-16 1998-02-19 The Dupont Merck Pharmaceutical Company Amidinophenyl-pyrrolidines, -pyrrolines et -isoxazolidines et leurs derives
WO1998016830A2 (fr) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Systeme de criblage par gouttelettes
JP2002518985A (ja) 1997-05-07 2002-06-25 ユニバーシティー・オブ・ピッツバーグ タンパク質イソプレニルトランスフェラーゼの阻害剤
AU7105800A (en) 1999-09-01 2001-03-26 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
ATE474568T1 (de) 2001-05-30 2010-08-15 Univ Michigan Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
AU2005265131B2 (en) 2004-06-17 2012-02-23 Infinity Discovery, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20060020004A1 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Isoxazolidine compounds for treatment of bacterial infections
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法

Also Published As

Publication number Publication date
US20110160259A1 (en) 2011-06-30
ES2537762T3 (es) 2015-06-11
MX2009005184A (es) 2009-10-12
US20070161690A1 (en) 2007-07-12
NZ577243A (en) 2011-12-22
US7842815B2 (en) 2010-11-30
CN101583606A (zh) 2009-11-18
RU2449996C2 (ru) 2012-05-10
HK1130057A1 (en) 2009-12-18
US20080306127A9 (en) 2008-12-11
GT200900123A (es) 2011-09-02
EP2094673B1 (fr) 2015-04-08
CN101583606B (zh) 2015-04-08
WO2008060569A1 (fr) 2008-05-22
BRPI0718606A2 (pt) 2013-12-17
RU2009121808A (ru) 2010-12-20
AU2007319848A1 (en) 2008-05-22
EP2094673A1 (fr) 2009-09-02
MY156754A (en) 2016-03-31
IL198597A0 (en) 2010-02-17
JP2010510214A (ja) 2010-04-02
AU2007319848B2 (en) 2012-05-03
JP2014055156A (ja) 2014-03-27
TN2009000182A1 (en) 2010-10-18
KR20090082284A (ko) 2009-07-29
NO20092306L (no) 2009-08-17
CA2669596C (fr) 2014-09-30
KR101530721B1 (ko) 2015-06-22
US8461191B2 (en) 2013-06-11
IL198597A (en) 2014-03-31
ECSP099398A (es) 2009-07-31
CA2669596A1 (fr) 2008-05-22

Similar Documents

Publication Publication Date Title
MA31067B1 (fr) Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison.
MA30673B1 (fr) Composes et procedes d'inhibition de l'interaction de proteines bcl avec des partenaires de liaison
HK1105963A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MA30144B1 (fr) Composes et procedes d'inhibition de l'interaction des proteines bcl avec des partenaires de liaison
MA31304B1 (fr) Molecules et procedes de modulation de proproteine convertase subtilisine/kexine de type 9 (pcsk9)
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
HK1107700A1 (en) Triazole compounds that modulate hsp90 activity
SG171682A1 (en) Iap bir domain binding compounds
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
TW200616612A (en) Method for the teatment of polycystic kidney disease field of invention
WO2005074633A3 (fr) Compositions et procédés permettant de caractériser, de réguler, de diagnostiquer et de traiter des cancers
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
TW200724140A (en) Hydantoin compounds
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
MA31526B1 (fr) Nouveaux herbicides
MA31562B1 (fr) Macrocycles et leurs utilisations
TW200730192A (en) Compositions for separation of a plurality of distinct targets from a sample
MA31061B1 (fr) Inhibiteurs de kinases.
TNSN06418A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MY155908A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
PL1819354T3 (pl) Sposoby i związki do leczenia cukrzycy
TW200621265A (en) Composition for treating tumor and/or preventing tumor transfer and recurrence
BG110157A (en) INDONAL COMPOUNDS USE FOR TREATMENT OF DISABILITY OF KNOWLEDGE COMPETENCE
HK1144253A1 (en) Inositol pyrophosphates determine exocytotic capacity
WO2006064324A3 (fr) Hydroxyethylamines a substitution heterocycloalkyl-benzyle